信胜科技本次发行的保荐人、主承销商为国信证券股份有限公司，签字保荐代表人为陈航飞、刘飞 翔。 截至招股说明书签署日，信胜控股持有公司47.62%的股权，为公司控股股东。王海江及姚晓艳夫 妇直接持有公司股份的比例为46.67%，通过信胜控股和海创投资控制公司的股份比例为52.38%，合计 控制公司99.05%的股份对应的表决权，系公司实际控制人。 (责任编辑：田云绯) 中国经济网北京1月9日讯 据北交所网站消息，北京证券交易所上市委员会定于2025年1月16日下午 14时召开2026年第5次审议会议，审议的发行人为浙江信胜科技股份有限公司（以下简称"信胜科 技"）。 信胜科技本次拟在北交所上市，拟募集资金44,935.53万元，分别用于年产11,000台（套）刺绣机机 架建设项目、年产33万套刺绣机零部件建设项目、信胜科技信息化系统升级建设项目、信胜科技研发中 心建设项目、补充流动资金项目。 ...

截至招股说明书签署日，国科科仪持有公司60,505,208股股份，占公司股份总数35.21%，系公司控 股股东。国科控股持有国科科仪100%股权，其通过国科科仪控制公司35.21%股份，系公司的实际控制 人。 (责任编辑：田云绯) 中科仪本次发行的保荐人、主承销商为招商证券股份有限公司，签字保荐代表人为孙越、王越。 中国经济网北京1月9日讯 据北交所网站消息，北京证券交易所上市委员会定于2025年1月16日上午 9时召开2026年第4次审议会议，审议的发行人为中国科学院沈阳科学仪器股份有限公司（以下简称"中 科仪"）。 中科仪本次拟在北交所上市，拟募集资金82,548.33万元，分别用于干式真空泵产业化建设项目、高 端半导体设备扩产及研发中心建设项目、新一代干式真空泵及大抽速干式螺杆泵研发项目。 ...

Core Viewpoint - Shenzhen Stock Exchange will hold its second listing review committee meeting on January 16, 2026, to review the initial public offering (IPO) of Tianhai Automotive Electronics Group Co., Ltd. [1] Group 1: IPO Details - Tianhai Electronics plans to list on the main board of the Shenzhen Stock Exchange, aiming to raise CNY 246,042.10 million for various projects including connector technology upgrades, harness production base, automotive electronics production base, smart transformation and information construction, and the Tianhai Intelligent Connected Vehicle Industry Research Institute and supporting projects [1] Group 2: Sponsorship and Shareholding Structure - The sponsor for Tianhai Electronics' IPO is China Merchants Securities Co., Ltd., with representatives Yan Jian and Zhang Qian [1] - As of the signing date of the prospectus, Guangzhou Industrial Control directly holds 38.5650% of the shares, Changsheng Intelligent holds 5.3812%, and Industrial Control Investment holds 1.0359%, with a combined direct holding of 44.9821% due to their unified control and action [1] - Guangzhou Industrial Control is the controlling shareholder, and the Guangzhou Municipal People's Government directly holds 90% of its shares, with the Guangzhou State-owned Assets Supervision and Administration Commission acting as the actual controller [1]

Core Insights - The latest medical insurance drug list has been officially implemented on January 1, 2026, marking the eighth consecutive year of optimization by the medical insurance department, aimed at enhancing both the efficiency of fund usage and the level of medication security for the public [1][2] Group 1: Drug List Adjustments - A total of 114 new drugs have been added to the list, covering critical areas such as oncology, chronic diseases, and rare diseases, including 10 specific drugs for rare diseases, providing more treatment options for patients [1] - The average price reduction for newly added drugs exceeds 60% due to national medical insurance negotiations, significantly lowering the financial burden on patients [1] Group 2: Fund Efficiency and Clinical Relevance - The adjustments are designed to ensure that the medical insurance fund is directed towards high-efficiency and urgently needed medications, removing those that are no longer supplied or have better alternatives [2] - Specific drugs have had their payment scope adjusted to better align with clinical realities, such as the change in coverage for a drug used to increase white blood cell counts [1] Group 3: Support for Innovation and Long-term Strategy - The introduction of a commercial insurance innovative drug directory alongside the basic medical insurance aims to create a multi-layered support system for diverse patient medication needs, alleviating long-term pressure on the medical insurance fund [2] - The new drug list supports high-value innovative drugs, encouraging pharmaceutical companies to shift from marketing-driven approaches to those focused on clinical value, fostering innovation in the pharmaceutical industry [2] Group 4: Patient-Centric Reforms - The adjustments represent a patient-centered reform driven by clinical needs, emphasizing the importance of timely integration of new drugs into hospital procurement lists and addressing practical challenges faced by patients [2] - A long-term mechanism involving collaboration among medical insurance departments, medical institutions, and companies is necessary to maximize the benefits of these reforms for the public [2]

Core Viewpoint - Ecovision Optoelectronics (688610.SH) is currently trading at 65.94 yuan, reflecting a decline of 1.85% and is in a state of breaking its initial public offering (IPO) price [1] Group 1: IPO Details - Ecovision Optoelectronics was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 19, 2023, with a public offering of 17 million shares at an issue price of 73.33 yuan per share [1] - The total amount raised from the IPO was 1.24661 billion yuan, with a net amount of 1.13511 billion yuan after deducting issuance costs [1] - The final net amount raised exceeded the original plan by 15.66 million yuan, as the company initially aimed to raise 1.11944 billion yuan [1] Group 2: Fund Allocation - The funds raised are intended for the construction of the company's headquarters industrial imaging core components project, the establishment of a machine vision research and development center, and to supplement working capital [1] Group 3: Issuance Costs - The total issuance costs for the IPO amounted to 111.49 million yuan, with the underwriting fees for the lead underwriter, China Merchants Securities Co., Ltd., being 89.52 million yuan [1]

Group 1 - The core point of the news is that Xinhongye (301310.SZ) is currently trading at 42.08 yuan, reflecting a decline of 1.45% and is in a state of breaking its initial public offering price [1] - Xinhongye was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on June 2, 2023, with a total issuance of 24.2747 million shares at an issuance price of 67.28 yuan per share [1] - The total funds raised from the initial public offering amounted to 163.32018 million yuan, with a net amount of 149.73692 million yuan after deducting issuance costs, which exceeded the original plan by 105.13692 million yuan [1] Group 2 - The company plans to distribute a cash dividend of 5 yuan (including tax) for every 10 shares, totaling 48.5493 million yuan, and will also increase capital by 4 shares for every 10 shares held, resulting in a total of 38.83944 million shares being distributed [2] - Xinhongye's upcoming stock issuance plan for 2025 aims to raise no more than 30 million yuan, with the net proceeds intended for various research and industrialization projects related to special cables and systems [2]

Group 1 - The core point of the news is that YN Technology (昱能科技) is currently trading at 54.30 yuan, reflecting a decline of 0.98% and is in a state of share price drop below its initial public offering (IPO) price [1] - YN Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 8, 2022, with an IPO price of 163.00 yuan per share and issued 20 million shares [1] - The total funds raised from the IPO amounted to 326 million yuan, with a net amount of 303.7 million yuan, exceeding the original plan by 2.481 billion yuan [1] Group 2 - The company announced a cash dividend of 2.2 yuan per share (including tax) and a capital reserve increase of 0.4 shares for every share held, totaling 176 million yuan in cash dividends and 32 million shares in capital increase, resulting in a new total share capital of 112 million shares [2] - The upcoming dividend plan for June 27, 2024, includes a distribution of 10 yuan per 10 shares and a capital increase of 4 shares for every 10 shares held, with the record date set for July 2, 2024 [2]

公司首次上市发行费用合计10,750.27万元，其中保荐、承销费用8,773.58万元。保荐机构中信建投 证券控制下的相关子公司中信建投投资有限公司的最终跟投数量为1,963,672股，跟投比例占首次公开发 行股票数量的比例为4.10%。 天宜新材2022年10月28日披露的2022年度向特定对象发行A股股票上市公告书显示，公司向特定对 象发行111,438,808股，发行价格为20.81元/股，募集资金总额为2,319,041,594.48元，扣除发行费用后的 募集资金2,296,586,846.24元。公司本次的保荐机构为中信证券股份有限公司，保荐代表人为李宁、王泽 师。 中国经济网北京1月9日讯 天宜新材(688033.SH)今日收报8.39元，跌幅2.44%。 天宜新材2019年7月22日在上交所科创板上市，发行47,880,000股，发行价格为20.37元/股，保荐机 构为中信建投证券股份有限公司，保荐代表人为林郁松、赵启。目前公司股价处于破发状态。2019年8 月6日，公司盘中股价达到上市以来最高点64.80元，此后一路震荡下跌。 公司发行募集资金总额为97,531.56万元，扣除发行费用后的募集 ...

Group 1 - The company *ST Taihe (605081.SH) closed at 10.85 yuan, with a decline of 2.43% [1] - Shanghai Taihe Water Technology Development Co., Ltd. was listed on the Shanghai Stock Exchange on February 9, 2021, with an issuance of 19.53 million shares at a price of 43.30 yuan per share [1] - The highest price recorded on the first day of trading was 62.35 yuan, indicating that the stock is currently in a state of decline [1] Group 2 - The total amount raised from the initial public offering (IPO) was 84.5649 million yuan, with a net amount of 77.81094 million yuan [1] - The funds raised are intended for supplementing working capital for engineering construction, as well as for the headquarters operation center and information technology construction projects [1] - The total issuance costs for the IPO amounted to 6.75396 million yuan, including underwriting and sponsorship fees of 5.23725 million yuan [1] Group 3 - On May 26, 2022, the company announced a cash dividend distribution of 1 yuan per share (including tax) and a capital reserve increase of 0.45 shares per share, resulting in a total distribution of 78.101429 million yuan in cash dividends and an increase of 35.145643 million shares [2] - After the distribution, the total share capital increased to 113.247072 million shares [2] - The stock name changed from "Taihe Water" to "*ST Taihe" on April 29, 2025 [2]

Group 1 - The core point of the news is that Hansoh Pharmaceutical announced the approval of a fifth indication for Amelot (Ametinib Mesylate Tablets) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [1] - The approval is based on the AENEAS2 Phase III clinical study, which demonstrated that Amelot combined with chemotherapy significantly extends progression-free survival (PFS) compared to monotherapy, with a hazard ratio (HR) of 0.47, indicating a 53% reduction in the risk of disease progression or death [1] - The median PFS was extended to 28.9 months, with an objective response rate (ORR) of 93.2%, and no new safety risks were identified in the study, which included only Chinese patients [1] Group 2 - Since its initial approval in March 2020, Amelot has expanded from a single indication to five, with all previous indications included in the national medical insurance catalog, enhancing its clinical position and providing high-level evidence for the treatment of lung cancer in China [2] - The previously approved indications include postoperative adjuvant therapy for EGFR-mutant NSCLC, maintenance therapy after chemoradiotherapy for unresectable locally advanced NSCLC, and first-line and second-line treatments for advanced NSCLC [2]